Carvedilol Tablets Recalled Due to CGMP Manufacturing Deviations
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Carvedilol Tablets, USP 12.5 mg due to CGMP (Current Good Manufacturing Practice) deviations. The recall affects specific lots distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source states FDA Class II classification. No illnesses, injuries, or adverse health reports are documented in the source text. The recall is based on manufacturing process deviations (CGMP) rather than a detected product quality failure or actual harm, placing it at the lower end of Class II—a voluntary precautionary recall.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Carvedilol Tablets, USP 12.5 mg in 500-count bottles (NDC# 68462-164-05) due to deviations from Current Good Manufacturing Practice (CGMP) standards. The recall affects four lots: 17240238, 17240243, 17240245, and 17240248, all with January 2026 expiration dates.
The recalled product was manufactured by Glenmark Pharmaceuticals Limited in Pithampur, Madhya Pradesh, India and distributed nationwide in the United States. This is a Class II recall, which the FDA issues when a product defect may cause adverse health consequences or serious adverse effects.
Patients should not stop taking carvedilol without consulting their healthcare provider, as abrupt discontinuation of this heart medication can be harmful. Patients should contact their pharmacy to determine if their supply is affected and speak with their doctor about next steps. Healthcare providers and consumers with questions can contact the FDA or the recalling firm.
The recalled product
- Product
- CARVEDILOL (CARVEDILOL)
- Brand
- CARVEDILOL
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot # 17240238
- exp. date Jan-26 17240243
- exp. date Jan-26 17240245
- exp. date Jan-26 17240248
- exp. date Jan-26
UPCs (4)
- 0368462162019
- 0368462163016
- 0368462164013
- 0368462165010
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · CARVEDILOL
- HighMajor Pharmaceuticals carvedilol tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-27
- HighGlenmark carvedilol 25 mg tablets exceed the acceptable nitrosamine intake level
FDA (Drugs) · 2025-08-20
- HighGlenmark carvedilol 12.5 mg tablets exceed the nitrosamine impurity limit
FDA (Drugs) · 2025-08-20
- HighCarvedilol 25 mg tablets recalled over nitrosamine impurity above FDA limit
FDA (Drugs) · 2025-08-20
- HighCarvedilol 12.5 mg tablets recalled over nitrosamine above acceptable intake level
FDA (Drugs) · 2025-08-20
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09